Spots Global Cancer Trial Database for Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
Official Title: A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice
Study ID: NCT01242072
Interventions
Study Description
Brief Summary: This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Horizon Oncology Research, Lafayette, Indiana, United States
Medical Consultants, PC, Muncie, Indiana, United States
Washington University, St. Louis, Missouri, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
